BRIEF published on 12/24/2024 at 20:51, 4 months 1 day ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 4 months 1 day ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
BRIEF published on 11/13/2024 at 07:35, 5 months 13 days ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
PRESS RELEASE published on 11/13/2024 at 07:30, 5 months 13 days ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
BRIEF published on 11/01/2024 at 18:23, 5 months 25 days ago GenSight Biologics Secures €2.8 Million Financing Warrants Financing Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 11/01/2024 at 18:18, 5 months 25 days ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
BRIEF published on 10/24/2024 at 21:13, 6 months 1 day ago GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ® Treasury Funding LUMEVOQ® ANSM Compassionate Access
PRESS RELEASE published on 10/24/2024 at 21:08, 6 months 1 day ago Inside Information / News release on accounts, results GenSight Biologics reports €3.4 million cash position as of September 30, 2024, updates on LUMEVOQ® drug product status, and financial discussions for future funding Cash Position Financial Update GenSight Biologics LUMEVOQ AAC Resumption
BRIEF published on 10/17/2024 at 07:35, 6 months 9 days ago GenSight Biologics Presents LUMEVOQ® Data at AAO 2024 Gene Therapy GenSight Biologics LUMEVOQ® LHON AAO 2024
PRESS RELEASE published on 10/17/2024 at 07:30, 6 months 9 days ago Inside Information / Other news releases GenSight Biologics to present scientific updates on LUMEVOQ® gene therapy at AAO 2024, including real-world experience and long-term outcomes for LHON patients Gene Therapy GenSight Biologics LHON LUMEVOQ AAO 2024
Published on 04/26/2025 at 02:00, 18 hours 45 minutes ago Battery X Metals Announces Strategic Agreement to Advance Artificial Intelligence-Driven Exploration of Critical Battery Metals in Nevada, USA
Published on 04/25/2025 at 23:30, 21 hours 15 minutes ago AIML Innovations Announces Departure of Tim Daniels from Board of Directors
Published on 04/25/2025 at 23:01, 21 hours 44 minutes ago Medicure Reports Financial Results for Quarter and Year Ended December 31, 2024
Published on 04/25/2025 at 23:00, 21 hours 45 minutes ago AIML Optimizes Quantum Sciences Acquisition to Drive Growth & Strategic Focus
Published on 04/25/2025 at 22:15, 22 hours 30 minutes ago Grande Portage Resources Announces Extension of Expiry Date for Warrants
Published on 04/25/2025 at 22:47, 21 hours 58 minutes ago DEAG achieves new revenue level in “transformation year” 2024 – Strategic investments and strong start to the year create basis for future sustainable growth
Published on 04/25/2025 at 20:30, 1 day ago EQS-Adhoc: Nagarro SE: Confirms 2024 guidance and dividend, postpones publication for full-year results
Published on 04/25/2025 at 18:44, 1 day 2 hours ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 04/25/2025 at 18:31, 1 day 2 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/25/2025 at 18:30, 1 day 2 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/25/2025 at 18:05, 1 day 2 hours ago Louis Hachette Group - 2025 First-quarter revenue
Published on 04/25/2025 at 18:00, 1 day 2 hours ago Availability of the 2024 universal registration document
Published on 04/25/2025 at 18:00, 1 day 2 hours ago Postponement of the publication of the annual financial statements
Published on 04/25/2025 at 17:45, 1 day 3 hours ago LANSON-BCC: GENERAL SHAREHOLDERS’ MEETING ON APRIL 25, 2025 - DIVIDEND: €0.90 PER SHARE
